Generic Products

In addition to drug products based on our proprietary delivery system, we have a portfolio of generic product candidates with favorable commercial agreements that supplement our branded pipeline.

ivermectin cream, 1%


Tentative Approval as of January 2018

acyclovir cream, 5%


Approval & Sales as of February 2019

5-fluorouracil cream, 5%


Bioequivalence Study Completed December 2019

Additional R&D

In addition to advancing our lead product candidates, we are also engaged in the formulation and pre-clinical development of early stage innovative product candidates for both current focus indications, such as acne and rosacea, and for other dermatological indications.